---
layout: default
title: Metoprolol
description: "Metoprolol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 105
evidence_level: L5
indication_count: 10
---

# Metoprolol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Metoprololï¼šå¾ é«˜è¡€å£“ åˆ° æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šèˆ‡æ…¢æ€§è‚ºå¿ƒç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Metoprolol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Metoprololï¼ˆç¾æ‰˜æ™®æ´›ï¼‰æ˜¯ä¸€ç¨®é¸æ“‡æ€§ beta-1 è…ä¸Šè…ºç´ å—é«”é˜»æ–·åŠ‘ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡å’Œå¿ƒå¾‹ä¸æ•´ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š (malignant hypertensive renal disease)** å’Œ**æ…¢æ€§è‚ºå¿ƒç—… (chronic pulmonary heart disease)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰è¶…é **15 é …è‡¨åºŠè©¦é©—**æ”¯æŒæ…¢æ€§è‚ºå¿ƒç—…ç›¸é—œæ‡‰ç”¨ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ã€å¿ƒå®¤ä¸Šå¿ƒå¾‹ä¸æ•´ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | hypertensive disorderã€malignant hypertensive renal diseaseã€malignant renovascular hypertensionã€pulmonary hypertension owing to lung disease and/or hypoxiaã€pulmonary hypertension with unclear multifactorial mechanismã€Braddock syndromeã€myocardial infarctionã€posteroinferior myocardial infarctionã€posterolateral myocardial infarctionã€septal myocardial infarction |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.91% (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š), 99.40% (æ…¢æ€§è‚ºå¿ƒç—…) |
| è­‰æ“šç­‰ç´š | L2 (æ…¢æ€§è‚ºå¿ƒç—…), L5 (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 15+ å¼µ |
| å»ºè­°æ±ºç­– | Explore |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Metoprolol é€šéé¸æ“‡æ€§é˜»æ–·å¿ƒè‡Ÿ beta-1 å—é«”ï¼Œæ¸›å°‘å¿ƒç‡ã€å¿ƒè‚Œæ”¶ç¸®åŠ›å’Œå¿ƒè¼¸å‡ºé‡ï¼Œå¾è€Œé™ä½è¡€å£“å’Œå¿ƒè‚Œè€—æ°§é‡ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>


**æ©Ÿè½‰æ”¯æŒï¼ˆæ…¢æ€§è‚ºå¿ƒç—…ï¼‰ï¼š**
- Beta-blocker å¯æ”¹å–„å³å¿ƒåŠŸèƒ½
- æ¸›å°‘å¿ƒå¾‹ä¸æ•´é¢¨éšª
- åœ¨å¿ƒè¡°æ‚£è€…ä¸­è­‰å¯¦å¯é™ä½æ­»äº¡ç‡
- é¸æ“‡æ€§ beta-1 é˜»æ–·å°æ”¯æ°£ç®¡å½±éŸ¿è¼ƒå°

**æ©Ÿè½‰æ”¯æŒï¼ˆæƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šï¼‰ï¼š**
- é•·æ•ˆé™å£“ä½œç”¨
- æ¸›å°‘äº¤æ„Ÿç¥ç¶“éåº¦æ´»åŒ–
- å¯ä½œç‚ºè¡€å£“æ§åˆ¶çš„ç¶­æŒæ²»ç™‚

### è‡¨åºŠè©¦é©—

**æ…¢æ€§è‚ºå¿ƒç—…/COPD ç›¸é—œè©¦é©—ï¼š**

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | ä¸»è¦ç ”ç©¶ç›®æ¨™ |
|---------|------|------|-------------|
| NCT06825728 | Phase 4 | å°šæœªæ‹›å‹Ÿ | Metoprolol å° HFrEF åˆä½µ COPD æ‚£è€…çš„æ­»äº¡å’Œå†ä½é™¢å½±éŸ¿ |
| NCT03370835 | Phase 4 | å®Œæˆ | æ¯”è¼ƒ Metoprolol å’Œ Carvedilol åœ¨ COPD æ‚£è€…çš„è€å—æ€§ |
| NCT03778554 | Phase 4 | é€²è¡Œä¸­ | å¿ƒè‚Œæ¢—å¡å¾Œç„¡å¿ƒè¡°æ‚£è€…çš„ beta-blocker æ²»ç™‚ |
| NCT02587351 | Phase 3 | çµ‚æ­¢ | Metoprolol é é˜² COPD æ€¥æ€§æƒ¡åŒ– |
| NCT03566667 | Phase 4 | é€²è¡Œä¸­ | Beta-blocker å° COPD æ‚£è€…çš„ç›Šè™• |
| NCT00288548 | Phase 4 | æœªçŸ¥ | Metoprolol èˆ‡ Formoterol åˆç”¨å° COPD è‚ºåŠŸèƒ½çš„å½±éŸ¿ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|---------|
| [8737105](https://pubmed.ncbi.nlm.nih.gov/8737105/) | 1996 | RCT | Metoprolol vs Xamoterol å°å¿ƒè‚Œæ¢—å¡å¾Œå¿ƒè¡°æ‚£è€…å·¦å¿ƒåŠŸèƒ½çš„å½±éŸ¿ |
| [14711192](https://pubmed.ncbi.nlm.nih.gov/14711192/) | 2003 | å‹•ç‰©ç ”ç©¶ | ä¸åŒåŠ‘é‡ Carvedilol å’Œ Metoprolol é é˜²æ¢—å¡å¾Œå¿ƒå®¤é‡å¡‘çš„æ¯”è¼ƒ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Braddock syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. posteroinferior myocardial infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.84%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. posterolateral myocardial infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.84%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. septal myocardial infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. chronic pulmonary heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.40%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.40%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. trichotillomania</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.05%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.05%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è£½å­—ç¬¬029301è™Ÿ | "æ˜å¾·"å¿ƒå£“æš¢éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬029313è™Ÿ | "æˆå¤§"è²ä»–å¯§éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |
| è¡›ç½²è—¥è£½å­—ç¬¬031032è™Ÿ | "å¥å–¬"å¿ƒèˆ’å¯§éŒ 100æ¯«å…‹ | éŒ åŠ‘ | é«˜è¡€å£“ã€ç‹¹å¿ƒç—‡ |

## å®‰å…¨æ€§è€ƒé‡

**ç¦å¿Œç—‡ï¼š**
- åš´é‡ç«‡æ€§å¿ƒå‹•éç·©
- äºŒæˆ–ä¸‰åº¦æˆ¿å®¤å‚³å°é˜»æ»¯
- å¿ƒæºæ€§ä¼‘å…‹
- å¤±ä»£å„Ÿæ€§å¿ƒè¡°
- åš´é‡å‘¨é‚Šå‹•è„ˆç–¾ç—…

**COPD æ‚£è€…æ³¨æ„äº‹é …ï¼š**
- é¸æ“‡æ€§ beta-1 é˜»æ–·åŠ‘ç›¸å°å®‰å…¨
- ä½åŠ‘é‡èµ·å§‹ï¼Œç·©æ…¢èª¿æ•´
- ç›£æ¸¬è‚ºåŠŸèƒ½å’Œå‘¼å¸ç—‡ç‹€
- æœ‰æ”¯æ°£ç®¡ç—™æ”£ç—…å²è€…è¬¹æ…ä½¿ç”¨

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼š**
- Verapamil/Diltiazemï¼šå¢åŠ å¿ƒå‹•éç·©å’Œå‚³å°é˜»æ»¯é¢¨éšª
- Digoxinï¼šå¢å¼·å¿ƒå‹•éç·©æ•ˆæœ
- MAO æŠ‘åˆ¶åŠ‘ï¼šå¯èƒ½å¢å¼·é™å£“æ•ˆæœ
- Beta-agonist å¸å…¥åŠ‘ï¼šå¯èƒ½ç›¸äº’æ‹®æŠ—

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...

**é£Ÿç‰© (food)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe bioavailability of metoprolol may be enhanced by food.
- å»ºè­°ï¼šPatients may be instructed to take metoprolol at the same time each day, preferably with or immediately following meals.

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å¯èƒ½å¼•èµ·ä½è¡€é‰€ï¼Œå½±éŸ¿å¿ƒè‡Ÿè—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šç›£æ¸¬é›»è§£è³ª



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Cerebrovascular Disorders** ğŸŸ¡ Moderate
- Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blo...

**é’å…‰çœ¼ (Glaucoma)** ğŸŸ¡ Moderate
- Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or disc...

**Hyperlipidemias** ğŸŸ¡ Moderate
- Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patient...

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperthyroidism)** ğŸŸ¡ Moderate
- When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid st...

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperthyroidism)** ğŸŸ¡ Moderate
- During chronic administration, the clearance of beta-blockers that are primarily metabolized by the liver (e.g., labetalol, metoprolol, penbutolol, propranolol) may be increased in patients with hyperthyroidism due to increased liver blood flow and e...

*å¦æœ‰ 14 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
Metoprolol å°æ…¢æ€§è‚ºå¿ƒç—…çš„é æ¸¬å…·æœ‰è‡¨åºŠç›¸é—œæ€§ã€‚å¤šé …é€²è¡Œä¸­çš„è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼° beta-blocker åœ¨ COPD å’Œå¿ƒè¡°å…±ç—…æ‚£è€…ä¸­çš„æ•ˆç›Šå’Œå®‰å…¨æ€§ã€‚å‚³çµ±ä¸Šèªç‚º beta-blocker åœ¨ COPD ä¸­ç¦å¿Œï¼Œä½†è¿‘æœŸè­‰æ“šé¡¯ç¤ºé¸æ“‡æ€§ beta-1 é˜»æ–·åŠ‘å¯èƒ½å¸¶ä¾†æ·¨ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè¡€ç®¡å…±ç—…æ‚£è€…ä¸­ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç­‰å¾…é€²è¡Œä¸­è©¦é©—ï¼ˆå¦‚ NCT06825728, NCT03566667ï¼‰çµæœ
- ç¢ºå®š COPD åš´é‡ç¨‹åº¦èˆ‡æ²»ç™‚é¢¨éšª/æ•ˆç›Šçš„é—œä¿‚
- å»ºç«‹ COPD æ‚£è€…ä½¿ç”¨ beta-blocker çš„æœ€ä½³åŠ‘é‡ç­–ç•¥
- é–‹ç™¼é æ¸¬å“ªäº›æ‚£è€…æœ€å¯èƒ½å—ç›Šçš„ç”Ÿç‰©æ¨™è¨˜


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nefopam]({{ "/drugs/nefopam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Scopolamine]({{ "/drugs/scopolamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ethynodiol Diacetate]({{ "/drugs/ethynodiol_diacetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caspofungin]({{ "/drugs/caspofungin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Metoprololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/metoprolol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_metoprolol,
  title = {Metoprololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/metoprolol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
